SinoLink Securities Co., Ltd.'s verification opinion on the reply to the information disclosure regulatory inquiry letter of Shanghai Yizhong Pharmaceutical Co., Ltd.'s 2023 annual report.

SZSI · Jun 7

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.